Charles Schwab
NMRA icon

Charles Schwab’s Neumora Therapeutics NMRA Stock Holding History

Charles Schwab’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.4M Buy
823,583
+307,401
+60% +$585K ﹤0.01% 2903
2026
Q1 		$1.01M Buy
516,182
+3,712
+0.7% +$9.62K ﹤0.01% 2904
2025
Q4 		$917K Sell
512,470
-469
-0.1% -$1.03K ﹤0.01% 2949
2025
Q3 		$934K Buy
512,939
+69,772
+16% +$113K ﹤0.01% 2974
2025
Q2 		$325K Sell
443,167
-150,331
-25% -$114K ﹤0.01% 3286
2025
Q1 		$593K Sell
593,498
-110,656
-16% -$189K ﹤0.01% 3017
2024
Q4 		$7.46M Buy
704,154
+5,899
+0.8% +$70.7K ﹤0.01% 2146
2024
Q3 		$9.22M Buy
698,255
+406,891
+140% +$4.75M ﹤0.01% 2063
2024
Q2 		$2.86M Buy
291,364
+166,822
+134% +$1.73M ﹤0.01% 2580
2024
Q1 		$1.71M Sell
124,542
-5,370
-4% -$86.8K ﹤0.01% 2639
2023
Q4 		$2.21M Buy
+129,912
New +$1.59M ﹤0.01% 2584

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Charles Schwab's NMRA Position: Q2 2026 in Review

Charles Schwab increased its Neumora Therapeutics (NMRA) stake by 60% in Q2 2026, buying an estimated $585K and bringing the position to 823,583 shares worth $1.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2903.

Charles Schwab first reported a position in NMRA in Q4 2023 and has held it in 11 quarters since. The position peaked at $9.22M in Q3 2024. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Charles Schwab held 823,583 shares of Neumora Therapeutics worth $1.4M as of Q2 2026.
  • Charles Schwab bought 307,401 Neumora Therapeutics shares in Q2 2026, an estimated $585K.
  • Neumora Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2903 holding.
  • Charles Schwab first reported a position in Neumora Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Charles Schwab's Neumora Therapeutics position peaked at $9.22M in Q3 2024.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.